Hepatitis C virus(HCV) is a leading cause of several liver problems,such as chronic hepatitis,liver cirrhosis,and hepatocellular carcinoma1.An estimated 3.2million individuals in the United States and 170 million individuals worldwide are infected with HCV2.HCV entry is determined to be a highly orchestrated process involving several viral and host cell factors,therefore represents potential targets for therapeutic intervention3.Inhibitors of viral entry can add significantly to a drug cocktail targeting multi-steps of the viral life cycle.